OVERVIEW

PARP Inhibitors in Ovarian Cancer Course is organized by University of Florida (UF) College of Medicine.

Release Date: Feb 11, 2020
Expiration Date: Feb 10, 2022

CME Accreditation
The University of Florida College of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives Topics
As a result of participation in this activity, participants should be able to:
• Understand the relevance of homologous recombination deficiency (HRD) in development of ovarian cancer
• Discuss the mechanism of action and rationale for PARPi in ovarian cancer
• review the FDA-approved uses for PARPi in the management of advanced ovarian cancer